Bioresorbable foaming tissue dressing

Patent metadata

Field	Value
Publication number	US-9456860-B2
Application number	US-34779108-A
Country	US
Kind code	B2
Filing date	Dec 31, 2008
Priority date	Mar 14, 2006
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

Provided is a flowable bioresorbable tissue dressing comprising a gas-forming porogen and a gel or gel-forming solution. Also provided is kits for preparing the above-described tissue dressing. Further provided are methods of treating a tissue site of a mammal with the above dressing. Also provided is a reduced pressure delivery system for applying a reduced pressure tissue treatment to a tissue site.

First claim

What is claimed is:

1. A dressing for applying reduced-pressure treatment to a tissue site, comprising:
a gas-forming porogen comprising a particle size for developing sufficient porosity for conducting reduced pressure;
a bioresorbable microsphere; and
a bioresorbable gel or a bioresorbable gel-forming solution in a mixture with the gas-forming porogen and the bioresorbable microsphere;
wherein the mixture is flowable, and after delivery to the tissue site, forms a scaffold comprising pores of at least 50 micrometers in diameter for delivering reduced pressure through the scaffold; and
wherein the dressing is bioresorbable.

2. The dressing of claim 1 , wherein the porogen is a mixture of an acid and a carbonate salt.

3. The dressing of claim 2 , wherein the acid is citric acid.

4. The dressing of claim 2 , wherein the carbonate salt is ammonium bicarbonate, sodium bicarbonate or calcium carbonate.

5. The dressing of claim 1 , wherein the gel or gel-forming solution comprises collagen, gelatin, hyaluronic acid, or combinations thereof.

6. The dressing of claim 1 , further comprising a non-gas forming porogen.

7. The dressing of claim 6 , wherein the non-gas forming porogen is a salt.

8. The dressing of claim 7 , wherein the salt is sodium chloride or potassium chloride.

9. The dressing of claim 6 , wherein the non-gas forming porogen is a sugar.

10. The dressing of claim 1 , wherein the bioresorbable microsphere comprises polylactide (PLA), polyglycolic acid (PLG), poly(lactide-co-glycolide) (PLGA), polyethylene glycol-PLA, PLA-polycaprolactone (PCL), a polyorthoester, a polyphosphazene, or a polyphosphoester.

11. The dressing of claim 1 , further comprising a compound that adds stiffness to the dressing.

12. The dressing of claim 11 , wherein the compound is calcium sulfate hemihydrate.

13. The dressing of claim 1 , further comprising a bioactive agent.

14. The dressing of claim 13 , wherein the bioactive agent is an antibiotic.

15. The dressing of claim 13 , wherein the bioactive agent is a growth factor.

16. The dressing of claim 15 , wherein the growth factor is growth hormone (GH), a bone morphogenetic protein (BMP), transforming growth factor-α(TGF-α), a TGF-β, a fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GMCSF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), an interleukin, tumor necrosis factor-α(TNF-α), or nerve growth factor (NGF).

17. The dressing of claim 1 , further comprising a mammalian cell.

18. The dressing of claim 17 , wherein the mammalian cell is an embryonic stem cell, an adult stem cell, an induced pluripotent stem cell, an epithelial cell, an endothelial cell, a mesenchymal cell, a muscle cell, a fibroblast, a chondrocyte, an adipocyte, or an osteocyte.

19. The dressing of claim 17 , wherein the mammalian cell is a human cell.

20. The dressing of claim 1 , wherein the pores of the scaffold are between approximately 50 micrometers and 1,500 micrometers in diameter.

21. The dressing of claim 1 , wherein the pores of the scaffold are between approximately 100 micrometers and 500 micrometers in diameter.

22. A tissue dressing for applying reduced-pressure treatment to a tissue site, comprising:
a gas-forming porogen comprising a particle size for developing sufficient porosity for conducting reduced pressure;
a bioresorbable microsphere; and
a gel or gel-forming solution in a mixture with the gas-forming porogen and the bioresorbable microsphere;
wherein the mixture is flowable, and after delivery to the tissue site, forms a scaffold comprising pores of at least 50 micrometers in diameter for delivering reduced pressure through the scaffold.

23. The dressing of claim 22 , wherein the porogen is a mixture of an acid and a carbonate salt.

24. The dressing of claim 23 , wherein the acid is citric acid.

25. The dressing of claim 23 , wherein the carbonate salt is ammonium bicarbonate, sodium bicarbonate or calcium carbonate.

26. The dressing of claim 22 , wherein the gel or gel-forming solution comprises a polyacrylate, a poloxamer, a polyethylene glycol, chitosan, collagen, gelatin, hyaluronic acid, or combinations thereof.

27. The dressing of claim 22 , wherein the gel or gel-forming solution comprises a combination of polyacrylate and chitosan.

28. The dressing of claim 22 , wherein the gel or gel-forming solution is thermoreversible.

29. The dressing of claim 22 , further comprising a non-gas forming porogen.

30. The dressing of claim 29 , wherein the non-gas forming porogen is a salt.

31. The dressing of claim 30 , wherein the salt is sodium chloride or potassium chloride.

32. The dressing of claim 29 , wherein the non-gas forming porogen is a sugar.

33. The dressing of claim 22 , wherein the bioresorbable microsphere comprises polylactide (PLA), polyglycolic acid (PLG), poly(lactide-co-glycolide) (PLGA), polyethylene glycol-PLA, PLA-polycaprolactone (PCL), a polyorthoester, a polyphosphazene, or a polyphosphoester.

34. The dressing of claim 22 , further comprising a compound that adds stiffness to the dressing.

35. The dressing of claim 34 , wherein the compound is calcium sulfate hemihydrate.

36. The dressing of claim 22 , further comprising a bioactive agent.

37. The dressing of claim 36 , wherein the bioactive agent is an antibiotic.

38. The dressing of claim 36 , wherein the bioactive agent is a growth factor.

39. The dressing of claim 38 , wherein the growth factor is growth hormone (GH), a bone morphogenetic protein (BMP), transforming growth factor-α(TGF-α), a TGF-β, a fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GMCSF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), an interleukin, tumor necrosis factor-α(TNF-α), or nerve growth factor (NGF).

40. The dressing of claim 22 , further comprising a mammalian cell.

41. The dressing of claim 40 , wherein the mammalian cell is an embryonic stem cell, an adult stem cell, an induced pluripotent stem cell, an epithelial cell, an endothelial cell, a mesenchymal cell, a muscle cell, a fibroblast, a chondrocyte, an adipocyte, or an osteocyte.

42. The dressing of claim 40 , wherein the mammalian cell is a human cell.

43. The tissue dressing of claim 22 , wherein the pores of the scaffold are between approximately 100 micrometers and 300 micrometers in diameter.

Assignees

• Ambrosio Archel
• Kci Licensing Inc

Inventors

• Ambrosio Archel

Classifications

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61B17/80

  Cortical plates {, i.e. bone plates; Instruments for holding or positioning cortical plates, or for compressing bones attached to cortical plates} · CPC title

• A61L26/008

  Hydrogels or hydrocolloids · CPC title

• A61L26/009 Primary

  Materials resorbable by the body · CPC title